18 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.
Celera Genomics
Development of activity-based probes for trypsin-family serine proteases.
Celera Genomics
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
University of Florida
Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone.
Johnson & Johnson Pharmaceutical Research & Development
Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.
Celera Genomics
Design, synthesis, and biological activity of potent and selective inhibitors of mast cell tryptase.
Aventis Pharmaceuticals
Combinatorial approaches towards the discovery of new tryptase inhibitors.
University of Barcelona
Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase.
Aventis Pharmaceuticals
Novel pyrazinone inhibitors of mast cell tryptase: synthesis and SAR evaluation.
Aventis Pharmaceuticals
Bivalent inhibition of beta-tryptase: distance scan of neighboring subunits by dibasic inhibitors.
Institut FüR Biochemie
Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors.
Axys Pharmaceuticals
Dibasic inhibitors of human mast cell tryptase. Part 1: synthesis and optimization of a novel class of inhibitors.
Axys Pharmaceuticals
Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.
Roche Pharma Research and Early Development